Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
15 juin 2024 08h45 HE
|
Agios Pharmaceuticals, Inc.
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights...
Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET
06 juin 2024 09h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
03 juin 2024 06h30 HE
|
Agios Pharmaceuticals, Inc.
– Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo – – Statistical Significance Achieved for All Key...
Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
30 mai 2024 16h05 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty
28 mai 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
– Royalty Pharma to Acquire Rights to Agios’ 15% Royalty on Potential Vorasidenib U.S. Net Sales for $905 Million Upfront upon FDA Approval of Vorasidenib; Agios to Share in Economics Above Certain...
Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress
14 mai 2024 10h00 HE
|
Agios Pharmaceuticals, Inc.
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional Presentations to Highlight Quality of Life Data from...
Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024
06 mai 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024
03 mai 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...
Agios Reports Business Highlights and First Quarter 2024 Financial Results
02 mai 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
– Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 – – Announced Positive Results from the...
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
18 avr. 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today...